IRONWOOD PHARMACEUTICALS, INC. Available-for-sale Securities, Amortized Cost Basis
IRONWOOD PHARMACEUTICALS, INC. (IRWD) had Available-for-sale Securities, Amortized Cost Basis of $95.76 million as of 2017-12-31, per its 10-K filed 2018-02-22.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-02-22
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $95.76M.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $62.78M.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $90.79M.
- 2017-03-31: Available-for-sale Securities, Amortized Cost Basis $162.06M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2017-12-31 | $95.76M 10-K · filed 2018-02-22 |
| 2017-09-30 | $62.78M 10-Q · filed 2017-11-02 |
| 2017-06-30 | $90.79M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $162.06M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $251.22M 10-K · filed 2018-02-22 |
| 2016-09-30 | $136.88M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $48.00M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $153.50M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $178.19M 10-K · filed 2017-02-22 |
| 2015-09-30 | $214.18M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $236.84M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $152.17M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $174.06M 10-K · filed 2016-02-19 |
| 2014-09-30 | $213.67M 10-Q · filed 2014-11-05 |
| 2014-06-30 | $206.62M 10-Q · filed 2014-08-05 |
| 2014-03-31 | $127.15M 10-Q · filed 2014-04-29 |
| 2013-12-31 | $122.11M 10-K · filed 2015-02-18 |
| 2013-09-30 | $97.92M 10-Q · filed 2013-10-28 |
| 2013-06-30 | $81.08M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $136.72M 10-Q · filed 2013-04-23 |
| 2012-12-31 | $31.52M 10-K · filed 2014-02-07 |
| 2012-09-30 | $67.45M 10-Q · filed 2012-11-06 |
| 2012-06-30 | $70.58M 10-Q · filed 2012-08-07 |
| 2012-03-31 | $70.49M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $76.73M 10-K · filed 2013-02-21 |
| 2010-12-31 | $203.70M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |